{
  "source": "PA-Notification-Truqap.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1429-2\nProgram Prior Authorization/Notification\nMedication TruqapTM (capivasertib)\nP&T Approval Date 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nTruqap (capivasertib) is a kinase inhibitor indicated, in combination with fulvestrant, for the\ntreatment of adult patients with hormone receptor (HR)-positive, human epidermal growth\nfactor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or\nmore PIK3CA/AKT1/PTEN-alterations following progression on at least one endocrine-\nbased regimen in the metastatic setting or recurrence on or within 12 months of completing\nadjuvant therapy.\n2. Coverage Criteria a:\nA. Patients less than 19 years of age\n1. Truqap will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Breast Cancer\n1. Initial Authorization\na. Truqap will be approved based on all of the following criteria:\n(1) Diagnosis of breast cancer\n-AND-\n(2) One of the following:\n(a) Locally advanced\n(b) Recurrent unresectable (local or regional)\n(c) Metastatic\n-AND-\n(3) Disease is hormone receptor (HR)-positive\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(4) Disease is human epidermal growth factor receptor 2 (HER2)-negative\n-AND-\n(5) Presence of one or more PIK3CA/AKT1/PTEN-alterations\n-AND-\n(6) One of the following:\n(a) Has progressed on at least one endocrine-based regimen in the metastatic\nsetting (e.g., anastrozole, letrozole, exemestane, tamoxifen)\n(b) Recurrence on or within 12 months of completing adjuvant therapy\n-AND-\n(7) Used in combination with fulvestrant\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Truqap will be approved based on both of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Truqap therapy\n-AND-\n(2) Used in combination with fulvestrant\nAuthorization will be issued for 12 months.\nC. NCCN Recomme",
    "g criteria:\n(1) Patient does not show evidence of progressive disease while on Truqap therapy\n-AND-\n(2) Used in combination with fulvestrant\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\n1. The drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n© 2025 UnitedHealthcare Services, Inc.\n2\n• Supply limits may be in place.\n4. References:\n1. Truqap [package insert]. Wilmington, DE: Astra Zeneca; September 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nNovember 25, 2024.\nProgram Prior Authorization/Notification - TruqapTM (capivasertib)\nChange Control\n1/2024 New program\n1/2025 Annual review. Added ‘recurrent unresectable’ to disease type of the\nclinical criteria. Added reference.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}